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Abstract
Background: Gene expression in skeletal muscle is controlled by a family of basic helix-loop-helix transcription
factors known as the myogenic regulatory factors (MRFs). The MRFs work in conjunction with E proteins to
regulate gene expression during myogenesis. However, the precise mechanism by which the MRFs activate gene
expression is unclear. In this work, we sought to define the binding profiles of MRFs and E proteins on muscle-
specific genes throughout a time course of differentiation.
Results: We performed chromatin immunoprecipitation (ChIP) assays for myogenin, MyoD, Myf5 and E proteins
over a time course of C2C12 differentiation, resulting in several surprising findings. The pattern of recruitment is
specific to each promoter tested. The recruitment of E proteins often coincides with the arrival of the MRFs, but
the binding profile does not entirely overlap with the MRF binding profiles. We found that E12/E47 is bound to
certain promoters during proliferation, but every gene tested is preferentially bound by HEB during differentiation.
We also show that MyoD, myogenin and Myf5 have transient roles on each of these promoters during muscle
differentiation. We also found that RNA polymerase II occupancy correlates with the transcription profile of these
promoters. ChIP sequencing assays confirmed that MyoD, myogenin and Myf5 co-occupy promoters.
Conclusions: Our data reveal the sequential association of MyoD, myogenin, Myf5 and HEB on muscle-specific
promoters. These data suggest that each of the MRFs, including Myf5, contribute to gene expression at each of the
geness analyzed here.. The dynamic binding profiles observed suggest that MRFs and E proteins are recruited
independently to promoters.
Background
The entire process of skeletal muscle differentiation is
controlled by four highly related basic helix-loop-helix
(bHLH) proteins referred to as the myogenic regulatory
factors (MRFs). The MRFs have distinct but overlapping
patterns of gene expression during muscle development
[1]. Gene knockouts of each factor in the mouse have
revealed that each MRF has a unique role in skeletal
muscle differentiation. Myf5, Myf6 (also known as
MRF4) and MyoD are not required for viability, although
each mutant has a distinct phenotype [2]. In the com-
bined absence of Myf5, Myf6 and MyoD, myoblasts are
not specified and no skeletal muscle forms, resulting in a
lethal phenotype [3]. Myogenin is the only MRF singly
required for viability [4,5]. Mice heterozygous for the null
allele appear normal, while mice lacking myogenin die at
birth. The myogenin- n u l lm i c eh a v em y o b l a s t s ,b u tv e r y
few muscle fibers. This suggests that myogenin is not
required for the specification of skeletal muscle, but is
required for the later stages of myofiber fusion.
MyoD and myogenin have been shown to bind highly
overlapping gene sets, although certain genes appear to
be selective for either factor [6,7]. However, the high
degree of overlap in the binding patterns suggests that
the majority of genes utilize both factors to activate gene
expression. Previous work has shown that certain genes
require the sequential expression of both MyoD and
myogenin to activate gene expression [7]. The present
work suggests that the activation of specific targets
requires MyoD and its associated chromatin-modifying
activities before myogenin can activate transcription.
Why MyoD cannot activate transcription without
myogenin on these genes is still unknown.
Recent work on Myf5 has revealed unexpected roles
for this factor in adult animals. As mentioned above,
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genesis. The role of Myf5 in later stages is unclear. In
the absence of MyoD, Myf6 or myogenin, Myf5 is
unable to promote differentiation from myoblasts [8].
This finding suggests that Myf5 functions only in mus-
cle progenitor cells (MPCs) and myoblasts. However,
recent work has shown that Myf5-null mice exhibit
impaired muscle regeneration with a significant increase
in muscle fiber hypertrophy and a delay in differentia-
tion [9]. However, satellite cell numbers were not signif-
icantly altered in the Myf5-null animals, although a
modest impaired proliferation was observed under some
conditions in vitro. This work highlights the questions
still remaining about the roles of the MRFs at distinct
stages in myogenesis.
All bHLH transcription factors function as either
homodimers or heterodimers. The bHLH transcription
factors are loosely grouped into several categories: the
widely expressed E proteins, including the E2A gene pro-
ducts E12 and E47, HEB, E2-2 and Daughterless, are in
the class I category and the MRF family is included in the
tissue-specific class II category. Class II bHLH proteins
form weak homodimers and preferentially heterodimer-
ize with E proteins [10]. Prior in vitro experiments have
demonstrated that the class II MRFs form avid heterodi-
mers with class I E proteins, but homodimerize poorly in
the presence of DNA sites [11-14]. Thus, it is thought
that the MRFs function as heterodimers with ubiquitous
E proteins. The E proteins suggested to be involved in
skeletal muscle differentiation are the E2A gene products
E12 and E47, as well as HEB. Recent work has suggested
that HEB may be the primary E protein that regulates
skeletal muscle differentiation [15].
The MRFs all bind the canonical E-box consensus
sequence, CANNTG. Genome-wide binding studies have
revealed that both MyoD and myogenin preferentially
bind E boxes with a consensus sequence of CASCTG
(International Union of Pure and Applied Chemistry
nomenclature http://www.iupac.org), where S represents
G or C [7,16]. The site recognized at the highest fre-
quency is CAGCTG. The sequences flanking the E box
also make important contributions to the binding affinity
and contribute to the overall consensus sequence
elements determined for MyoD and myogenin [11,16].
Given the high degree of overlap detected in the gen-
ome occupancy of MyoD and myogenin, we were inter-
ested in understanding the binding profile of these
factors over a time course of differentiation. We were
also interested in the binding profile of Myf5, as binding
data for this factor during differentiation have not been
reported. We also sought to compare the DNA-bound
profiles of the MRFs with the E proteins. Thus, we
initiated a temporal analysis of the binding of MyoD,
Myf5, myogenin and the E proteins in C2C12 cells, a
widely used cell culture model for myoblast differentia-
tion. These binding profiles were correlated with the
levels of mRNA present in the cells, the levels of RNA
polymerase II (RNAP II) occupancy and histone H3
acetylation present at the promoters. We show several
novel findings. Surprisingly, we have found that the pat-
tern of recruitment is unique to each gene, although
some common features arise. As others have observed,
we saw an early association of MyoD with most of these
genes. In a cooperative pattern, myogenin then binds
many of these promoters following MyoD. Unexpect-
edly, we found that Myf5 is also associated with genes
expressed late in differentiation and often colocalizes
with myogenin. We show that this colocalization also
occurs in vivo at a late embryonic time point. The bind-
ing of each of the MRFs is transient. We also show that
the occupancy of the E proteins is transient and that the
occupancy often peaks concurrently with the peak in
gene transcription. While the E2A gene products could
be detected on a few genes in our study in proliferating
cells, HEB does appear to be the dominant E protein
used during differentiation. At the genes occupied by
E12/E47 in early myogenesis, we detected a switch in
occupancy for HEB during differentiation. Taken
together, our data suggest new models for the recruit-
ment of MRFs and E proteins and support a novel role
for Myf5 during differentiation.
Results
Time course of MRF and E protein expression
To initiate this work, we first characterized the available
antibodies for these studies and confirmed MRF and E
protein expression patterns over a time course of differ-
entiation. We tested well-characterized antibodies for
MyoD and myogenin [17,18]. We found that antibodies
against MyoD and myogenin immunoprecipitated the
target protein (data not shown) and did not recognize
any of the other MRFs (Additional file 1 Figure S1). For
Myf5, we tested commercially available antibodies for
their ability to recognize and immunoprecipitate Myf5
specifically. We identified one antibody that immunopre-
cipitated Myf5 exclusively (Additional file 1 Figure S2),
and this antibody was used for all the studies presented.
We did note that the antibody does recognize recombi-
nant MyoD by using Western blot analysis, but we could
not immunoprecipitate this protein (Additional file 1 Fig-
ure S2). For the E proteins, we used antibodies raised
against HEB and the E2A gene products E12 and E47.
T h eH E Ba n t i b o d yr e c o g n i z e d E12/E47 on the basis of
Western blot analysis, but immunoprecipitated HEB spe-
cifically (Additional file 1 Figure S3). The antibody
against E12/E47 did not recognize or immunoprecipitate
recombinant HEB (Additional file 1 Figure S4). Next, we
examined the expression profile of the MRFs and HEB
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(Figure 1). As previously observed, MyoD and Myf5 were
expressed in proliferating myoblasts. MyoD levels
increased upon differentiation, but then rapidly decreased
after two days of differentiation. Unexpectedly, Myf5 was
expressed throughout the entire time course. Myogenin
was not detectable in proliferating cells, but was rapidly
upregulated upon differentiation. HEB was also expressed
in proliferating myoblasts, but was steadily downregu-
lated after about four days of differentiation. The E12/
E47 proteins were also expressed in proliferating myo-
blasts, but the expression decreased after two days of
differentiation.
Expression of genes chosen for analysis
Several genes were chosen for this analysis. We chose
muscle creatine kinase (Ckm) and desmin (Des), as both
are well-characterized genes whose expression increases
during differentiation. As the regulatory regions of these
genes have been studied extensively by others, promoter
proximal binding sites for the MRFs are well defined
[19-25]. We also chose the fast-twitch skeletal muscle
troponin I, type 2 (Tnni2)a n dleiomodin 2 (Lmod2)
genes, as these have been characterized as myogenin-
dependent targets in embryonic skeletal muscle during
embryogenesis, and the promoter proximal MRF bind-
ing sites are known [26]. We also chose titin cap
(Tcap), also known as telethonin.W eh a v er e c e n t l y
characterized the promoter proximal regulatory ele-
ments of the gene encoding Tcap and identified a pro-
moter proximal fragment that recapitulates the
expression pattern of Tcap in reporter assays and is
bound by myogenin in vivo [27]. For each of these
genes, we profiled the change in RNA expression pro-
files over a time course of differentiation.
For each gene, we saw that expression increased when
cells began to differentiate, as expected (Figure 2A).
Unexpectedly, we also observed that the expression con-
tinued to increase over several days of differentiationand
reached very high levels of expression after six days of
differentiation. We also observed that the expression
levels significantly decreased for each gene, with the
α-E12/47
α-HEB
α-myogenin
α-MyoD
α-Myf5
UD D1 D2 D3 D4 D6 D8 D9 D10
α-GAPDH
Figure 1 Expression of myogenic regulatory factors (MRFs) and E proteins over a time course of differentiation in C2C12 cells.C 2C12
cells were differentiated for the indicated number of days and harvested for protein (UD, undifferentiated cells; D1-D10, cells differentiated for
the indicated number of days). Protein concentration was determined for each extract and used to normalize the sample loading. Parallel blots
were probed for each of the indicated antibodies as described in Methods.
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conditions. We also wanted to compare the relative
expression levels of the chosen gene set. To perform
this analysis, we compared the expression of each gene
to a constitutive housekeeping gene, HPRT, in both
proliferating myoblasts and differentiated myotubes
(Figure 2B). This analysis revealed that Des was
expressed at a much higher level in proliferating myo-
blasts than any of the other genes examined in this
study. We also observed that Tnni2 and Des were
expressed at approximately the same high level in differ-
entiated cells. The expression levels of Lmod2, Tcap and
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Figure 2 Expression profiles of genes upregulated during skeletal muscle differentiation in C2C12 cells. (A) Expression profiles of
individual gene expression. Shown are graphs representing the change in expression of each gene examined in this study observed at each day
of differentiation with respect to the expression level detected in proliferating C2C12 myoblast cells. (B) The relative transcription levels of each of
the genes in this study under conditions of proliferation or differentiation are shown. Expression of each gene was determined by quantitative
real-time polymerase chain reaction (qRT-PCR) assay and normalized to HPRT levels. Numbers indicate the fold change between undifferentiated
samples (MB, myoblasts) and samples differentiated for six days (MT, myotubes). (A and B) Calculations of the relative fold changes in gene
expression and mRNA expression are described in Methods. qRT-PCR assays were performed in triplicate on cDNA samples derived from
independent RNA isolations. All data are normalized to the expression level of HPRT. Error bars represent standard deviations of the mean.
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of activation of Tnni2 or Des in this time course.
Binding of MRFs and E proteins to muscle-specific genes
Next, we profiled the binding of MyoD, myogenin, Myf5
and E proteins over the time course of differentiation
on each of these gene promoters. Proliferating cells and
cells differentiated for one, two, three, six and ten days
were used for the analysis. Surprisingly, we found that
the pattern of recruitment was specific to each gene
tested. First, we examined the well-characterized Ckm
promoter [20-22]. For this analysis, we chose to examine
the enhancer 1 element located upstream of the first
noncoding exon of Ckm that contains one E box with
t h es e q u e n c eC A G C T G ,t h ep r e f e r r e db i n d i n gs i t ef o r
MyoD and myogenin. In accordance with recent chro-
matin immunoprecipitation sequencing (ChIP-seq) stu-
dies for MyoD [16], we did not detect MyoD at the
Ckm enhancer in proliferating myoblasts (Figure 3). We
also did not detect myogenin, Myf5 or HEB at this time
point. After three days of differentiation, MyoD, myo-
genin and HEB were detectable at the Ckm enhancer.
However, six days after differentiation, we observed
greatly enriched binding of HEB and myogenin com-
pared to the relatively unchanged binding of MyoD. We
also detected Myf5 at this enhancer at this time point.
By ten days of differentiation, the MRFs and HEB
appeared to be departing the promoter. While the bind-
ing was significantly enrich e do v e rb a c k g r o u n df o ra l l
factors except MyoD, the levels at ten days of differen-
tiation were greatly reduced from those observed at six
days of differentiation. The dynamic profiles of the
MRFs and E proteins were surprising to us, so we also
compared the levels of RNAP II occupancy as a measure
of transcriptional activity. As histone H3 acetylation is
also a marker of active genes and increases in histone
H3 acetylation are correlated with MyoD binding, we
also examined the level of histone H3 acetylation at
these promoters. For these assays, we compared the
binding profile of RNAP II and acetylated histone H3
(AcH3) at two days of differentiation and at six days of
differentiation. We found that both RNAP II binding
and histone H3 acetylation increased at six days of dif-
ferentiation, consistent with the transcriptional profiling
and the increased occupancy of all the MRFs and HEB.
At Des, the most robustly expressed gene examined in
this study, we examined the previously characterized
promoter proximal enhancer element [24]. This region
immediately upstream of the transcriptional start site
contains one E box with the sequence CAGCTG. We
observed that MyoD bound to the Des promoter in
proliferating cells, again consistent with the recent
ChIP-seq study (Figure 4). MyoD remained bound to
the promoter as the cells differentiated, with the binding
ratio peaking at six days of differentiation. Myf5 and
HEB were also present on the Des promoter in prolifer-
ating cells. A peak of Myf5 binding was observed after
three days of differentiation, when a peak of myogenin
binding was also detected. By six days of differentiation,
Myf5 binding was still detectable, but at greatly reduced
levels. The levels continued to decrease after ten days of
differentiation. The level of HEB remained fairly con-
stant during the first two days of differentiation, but
began to increase after three days and steadily increased
until six days of differentiation. HEB remained bound to
the promoter after ten days of differentiation. Myogenin
was not detected at the promoter in proliferating cells.
Myogenin was detectable at the promoter after two days
of differentiation, and its levels were greatly increased
after three days of differentiation. The levels remained
high at six days of differentiation. After ten days of dif-
ferentiation, HEB levels remained relatively unchanged,
but the binding ratios of the MRFs were greatly
decreased. MyoD was no longer detected at the promo-
ter, and only low levels of both myogenin and Myf5
remained associated with the promoter. We observed
that RNAP II and AcH3 were associated with the pro-
moter after two days of differentiation, and, surprisingly,
those levels moderately decreased after six days of dif-
ferentiation. We note that the relative fold enrichment
of RNAP II and AcH3 was very high at Des,t h em o s t
highly expressed gene in this study. This indicates that
the number of Des promoters bound by RNAP II was
much higher than what was observed at other
promoters.
We next examined the Tnni2 promoter, which, like
Des, is highly expressed in differentiating C2C12 cells
(Figure 5). Previous work has shown that the expression
of Tnni2 is highly dependent on myogenin in vivo [26].
The regulatory elements of Tnni2 are uncharacterized, so
w ec h o s et oa n a l y z eah i g h l yc o n s e r v e dn o n c o d i n g
sequence immediately upstream of the transcriptional
start site. The transcriptional start site of Tnni2 is pre-
dicted to encode a short 5’ untranslated region (5’ UTR)
that initiates 23 bp prior to the translational start site.
The conserved noncoding region is approximately 300 bp
upstream of the start of transcription and contains two E
boxes. The sequence of the promoter distal E box is
CACCTG, while the sequence of the promoter proximal
E box is CAGCTG. The E boxes are separated by only
35 bp, so binding to either box could not be distin-
guished in our assay. As was true of Des, we observed an
association of MyoD with the Tnni2 promoter in prolifer-
ating cells. The levels remained relatively unchanged dur-
ing the time course of differentiation, although small
variations were observed. Myf5 was recruited to the pro-
moter upon the first day of differentiation, and the levels
continued to increase until after day six. By day ten of
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Page 5 of 18differentiation, Myf5 levels were greatly reduced. The
recruitment of HEB was particularly surprising at this
promoter. Here, we saw that HEB was not recruited to
the promoter before two days of differentiation. The
levels continued to increase at six days of differentiation,
but binding rapidly declined after this point. At this pro-
moter, the binding pattern of HEB completely overlapped
with the binding pattern of myogenin. Myogenin could
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Figure 3 Chromatin immunoprecipitation (ChIP) analysis of the muscle creatine kinase (Ckm)p r o m o t e r . Cross-linked extracts from
proliferating myoblasts (UD, undifferentiated cells) and myofibers in differentiation media for the indicated number of days (D1-D10) were
immunoprecipitated with antibodies against myogenin, MyoD, Myf5, HEB, RNA polymerase II (RNAP II), histone H3 acetylated at lysine 9 and/or
18 (H3 Ac9/18) or IgG. Immunoprecipitated DNA was purified and amplified with primers specific to the promoter of Ckm. Relative enrichment
at the IgH locus was used to normalize the data. The fold enrichment values were calculated as described in Methods.
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Page 6 of 18be detected at the promoter at two days of differentiation,
but binding was greatly enhanced after three days of dif-
ferentiation. The levels continued to increase at six days
of differentiation, but rapidly decreased after this point.
At Tnni2,w eo b s e r v e dt h a tw h i l eR N A PI Ia n dA c H 3
were present at two days of differentiation, the levels
significantly increased at six days of differentiation. After
six days of differentiation, AcH3 levels reached the very
high levels observed at Des.
The next promoter analyzed was the Lmod2 promoter
(Figure 6). The expression of Lmod2 is dependent on
myogenin during embryogenesis, and a promoter
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Figure 4 Chromatin immunoprecipitation (ChIP) analysis of the desmin (Des) promoter. Cross-linked extracts from proliferating myoblasts
(UD, undifferentiated cells) and myofibers in differentiation media for the indicated number of days (D1-D10) were immunoprecipitated with
antibodies against myogenin, MyoD, Myf5, HEB, RNA polymerase II (RNAP II), histone H3 acetylated at lysine 9 and/or 18 (H3 Ac9/18) or IgG.
Immunoprecipitated DNA was purified and amplified with primers specific to the promoter of Des. Relative enrichment at the IgH locus was
used to normalize the data. The fold enrichment values were calculated as described in Methods.
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Page 7 of 18proximal binding site for myogenin has been defined
[26]. A highly conserved noncoding region approxi-
mately 100 bp upstream of the predicted transcriptional
start site contains two E boxes. The transcriptional start
site of Lmod2 is immediately upstream of the transla-
tional start site, predicting a short 5’ UTR of 112 bp.
The sequence of the promoter proximal E box is
CAGCTG, while the sequence of the promoter distal
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Figure 5 Chromatin immunoprecipitation (ChIP) analysis of fast-twitch skeletal muscle troponin I, type 2 (Tnni2). Cross-linked extracts
from proliferating myoblasts (UD, undifferentiated cells) and myofibers in differentiation media for the indicated number of days (D1-D10) were
immunoprecipitated with antibodies against myogenin, MyoD, Myf5, HEB, RNA polymerase II (RNAP II), histone H3 acetylated at lysine 9 and/or
18 (H3Ac9/18) or IgG. Immunoprecipitated DNA was purified and amplified with primers specific to the promoter of Tnni2. Relative enrichments
at the IgH locus were used to normalize the data. The fold enrichment values were calculated as described in Methods.
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Page 8 of 18box E box is CAAATG. The E boxes are separated by
117 bp. Deletion of the promoter proximal E box in a
luciferase reporter assay largely abolished the transacti-
vation of the Lmod2 promoter by myogenin or MyoD
[26]. At the Lmod2 promoter, we saw that HEB was pre-
sent in proliferating cells, but none of the MRFs were
significantly present. MyoD and Myf5 were recruited
w i t hah i g ha f f i n i t yt ot h ep r o m o t e ro nt h ef i r s td a yo f
differentiation. Myogenin could be detected at this time
point, but the binding ratio was relatively low. The asso-
ciation of myogenin increased greatly by two days of dif-
ferentiation. Myogenin remained bound at six days of
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Figure 6 Chromatin immunoprecipitation (ChIP) analysis of the leiomodin 2 (Lmod2)p r o m o t e r . Cross-linked extracts from proliferating
myoblasts (UD, undifferentiated cells) and myofibers in differentiation media for the indicated number of days (D1-D10) were
immunoprecipitated with antibodies against myogenin, MyoD, Myf5, HEB, RNA polymerase II (RNAP II), histone H3 acetylated at lysine 9 and/or
18 (H3 Ac9/18) or IgG. Immunoprecipitated DNA was purified and amplified with primers specific to the promoter of Lmod2. Relative enrichment
at the IgH locus was used to normalize the data. The fold enrichment values were calculated as described in Methods.
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Page 9 of 18differentiation, but dissociated from the promoter by the
tenth day of differentiation. MyoD and Myf5, recruited
on the first day of differentiation, gradually dissociated
from the promoter after this time point. MyoD was
undetectable at three days of differentiation, while Myf5
remained associated with the promoter until sometime
after six days of differentiation. The occupancy of HEB
continued to increase during the initial stages of differ-
entiation, peaking at two days of differentiation. HEB
appeared to begin to dissociate from the promoter after
two days of differentiation. HEB was only weakly
detected at three days of differentiation and the levels
continued to decrease at six days of differentiation,
becoming undetectable by ten days of differentiation.
The levels of RNAP II and AcH3 were significantly
higher at six days of differentiation than at two days of
differentiation.
The final promoter analyzed was the Tcap promoter
(Figure 7). The Tcap locus contains a highly conserved
promoter proximal noncoding sequence that contains
two E boxes. Interestingly, neither the promoter proxi-
mal E box (CATCTG) nor the promoter distal E box
(CATGTG) is a favored binding site for MyoD or myo-
genin. However, MyoD and myogenin can activate this
promoter, and myogenin binds to the promoter during
embryogenesis [27]. In proliferating cells, none of the
MRFs or HEB is bound. At day one of differentiation,
MyoD was recruited to the Tcap promoter. MyoD
remained associated with the promoter until two days of
differentiation, but dissociated from the promoter by
t h r e ed a y so fd i f f e r e n t i a t i o n .T h i sr e s u l ti sc o n s i s t e n t
with our promoter characterization of Tcap,a sw eh a v e
shown that the promoter proximal E box is required for
both the activity in C2C12 cells and the activation by
MyoD in NIH3T3 cells [27]. Myogenin was not
recruited to the Tcap promoter at any time point tested,
which was surprising to us, as we have detected myo-
genin binding to the Tcap promoter in skeletal muscle
tissue during embryogenesis [27]. The profile of Myf5
was particularly surprising. Myf5 was not associated
with the promoter at early stages of differentiation, but
could be weakly detected at the promoter after six days
of differentiation. This binding increased greatly by ten
days of differentiation. HEB could be detected on the
Tcap promoter after two days of differentiation, when
MyoD was still present. However, by day three, MyoD
had departed the promoter and the occupancy of HEB
increased greatly at this time. The peak of HEB binding
appears to occur at three days of differentiation. By day
six, HEB was at the same low level observed at two days
of differentiation, and by ten days of differentiation it
was undetectable. We found the pattern of MRF and
HEB association at this gene particularly interesting, as
there is almost no overlap between these factors. MyoD
was recruited, followed by HEB, which then dissociated
as Myf5 arrived. At this promoter, we again observed
that RNAP II occupancy and H3 acetylation greatly
increased at six days of differentiation as compared to
two days of differentiation.
HEB replaces E12/E47 at specific promoters during
differentiation
At each of these promoters, we found the distinct pat-
tern of HEB binding very surprising. We had anticipated
seeing HEB bound to the promoter whenever an MRF
was bound. While there are overlaps, the pattern of
HEB binding is temporally controlled and unique to
each gene. We wondered if perhaps these findings could
be the result of the binding of the E2A gene products
E12 or E47 in a compensatory fashion. We reasoned
that E proteins might be associated at all time points,
b u tt h eEp r o t e i nc o u l db ee i t h e rE 1 2 / E 4 7o rH E B .T o
address this hypothesis, we repeated the ChIP assays on
proliferating cells, on cells differentiated for two days
and on cells differentiated for three days with antibodies
against the E2A gene products. In proliferating cells,
E12 or E47 could be detected at the Des and Lmod2
promoter binding sites (Figure 8A). For Lmod2,t h e
binding of E12/E47 was detected with HEB in proliferat-
ing cells, but E12/E47 was lost as cells began to differ-
entiate while HEB levels increased (Figure 8B). At two
days of differentiation, E12/E47 could still be detected at
the Des promoter, but that binding was lost at three
days of differentiation (Figure 8C). At both of these pro-
moter binding sites, we observed an exchange of E12/
E47 and HEB as cells began to differentiate. E12/E47
was not detected on any of the other promoters assayed
in this study. We have analyzed additional promoter
proximal elements of differentiation-specific genes and
have found that E12/E47 was associated with the myo-
genin(myog), troponin C, type 2(Tnnc2) and myosin
heavy chain 3 (Myh3) promoters in undifferentiated
cells as well (Additional file 1 Figure S5A). We did not
observe an association with the troponin T, type 2
(Tnnt2) promoter. In each case, binding was lost by two
days of differentiation (data not shown). HEB was
observed on the Tnnt2, Myh3 and Tnnc2 promoters
following two days of differentiation (Additional file 1
Figure S5B). For the majority of the promoters analyzed
here, it appears that HEB is the predominant E protein
recruited during differentiation and that the transient
association of HEB is not compensated by an overlap-
ping pattern of E12/E47. These data are consistent with
previously reported data that have established an impor-
tant role for HEBb in inducing differentiation [15].
Next, we asked whether the presence of HEB is required
to displace E12/E47 from promoters as cells begin to
differentiate. HEB levels were depleted with small
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Page 10 of 18hairpin (shRNA) constructs targeting HEB. Stable cell
lines expressing these constructs were screened for
expression of HEB and E12/E47. We proceeded with a
construct that showed a 73% knockdown of HEB
expression by RNA analysis (Figure 8D) and a reduction
in protein expression by Western blot analysis (Figure
8E). No change in E12/E47 expression was detected by
gene expression analysis (data not shown). ChIP assays
with antibodies against E12/E47 were performed on
cells differentiated for two days. We saw no enhanced
association of E12/E47 in cells reduced in expression of
HEB (Figure 8F), indicating that HEB is not required for
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Figure 7 Chromatin immunoprecipitation (ChIP) analysis of the titin cap (Tcap)p r o m o t e r . Cross-linked extracts from proliferating
myoblasts (UD, undifferentiated cells) and myofibers in differentiation media for the indicated number of days (D1-D10) were
immunoprecipitated with antibodies myogenin, MyoD, Myf5, HEB, RNA polymerase II (RNAP II), histone H3 acetylated at lysine 9 and/or 18 (H3
Ac9/18) or IgG. Immunoprecipitated DNA was purified and amplified with primers specific to the promoter of Tcap. Relative enrichment at the
IgH locus was used to normalize the data. The fold enrichment values were calculated as described in Methods.
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Figure 8 E12/E47 and HEB exchange at the leiomodin 2 (Lmod2) and desmin (Des) promoters. (A) E12/E47 binds to the promoters of Des
and Lmod2 in myoblasts. Cross-linked extracts from proliferating myoblasts (UD, undifferentiated cells) were immunoprecipitated with antibodies
against the E2A gene products. Immunoprecipitated DNA was purified and amplified with primers specific to the promoters of Ckm, Des, Tnni2,
Lmod2 and Tcap. (B) E12/E47 and HEB exchange at the Lmod2 promoter. Cross-linked extracts from proliferating myoblasts and myofibers in
differentiation media for two days were immunoprecipitated with antibodies against the E2A gene products, HEB or IgG. Immunoprecipitated
DNA was purified and amplified with primers specific to the promoter of Lmod2. (C) E12/E47 and HEB exchange at the Des promoter. Cross-
linked extracts from myofibers in differentiation media for two or three days were immunoprecipitated with antibodies against the E2A gene
products, HEB or IgG. Immunoprecipitated DNA was purified and amplified with primers specific to the promoter of Des. Relative enrichment at
the IgH locus was used to normalize the data. The fold enrichment values were calculated as described in Methods. (D) Gene expression analysis
of HEB in cells expressing a small hairpin RNA (shRNA) construct targeting HEB or a scrambled control (scr). (E) Western blot analysis of the cells
described in Figure 8D. The Western blot was probed with antibodies against HEB. (F) HEB is not required to displace E12/E47 at promoters.
Results of chromatin immunoprecipitation assays performed after two days of differentiation on HEB-depleted cells and the scr control are
shown.
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differentiation.
Myogenin, MyoD and Myf5 co-occupy promoters
We were particularly interested in the binding profile of
Myf5. For each gene tested, Myf5 had a unique binding
pattern that was distinct from the binding patterns of
MyoD and myogenin. We were surprised to observe
that the profile of Myf5 overlapped with myogenin at
several genes. To understand whether Myf5 and myo-
genin also colocalized during embryonic muscle devel-
opment, we repeated the ChIP experiments in skeletal
muscle tissue derived from embryonic day 18.5 (E18.5)
embryos. We chose E18.5 as it is late in embryogenesis
and is a time point at which myogenin is assumed to be
highly active. Myf5 is known to function only during the
early stages of myogenesis and thus would not be
expected to contribute to gene expression at this stage.
Moreover, Myf5 transcripts are not observed in embryos
after E14 [28]. However, we detected Myf5 protein in
hindlimb samples at late embryonic stages (Additional
file 1 Figure S6). As expected, we detected myogenin at
several muscle-specific promoters, including Lmod2 and
Des (Figure 9A). Consistent with our C2C12 data, Myf5
colocalized with myogenin at both of these promoters
in vivo (Figure 9A). After confirming that myogenin and
Myf5 appear to bind to the same sequences at a late
time point in embryogenesis, we were very interested in
understanding whether the overlapping pattern was
occurring in two cell populations or whether Myf5,
myogenin and MyoD co-occupy promoters. To address
this question, we performed sequential ChIP(ChIP-seq)
assays for myogenin, MyoD and Myf5 in C2C12 cells. To
address whether Myf5 and myogenin co-occupy promo-
ters, cells were differentiated for three days, immunopre-
cipitated with Myf5 antibodies and subsequently
immunoprecipitated with antibodies against myogenin.
We detected co-occupancy of Myf5 and myogenin at
the Tnni2 and Des promoters (Figure 9B). We also per-
formed the experiment with antibodies against myo-
genin first, followed by immunoprecipitation with Myf5
antibodies, and, again, co-occupancy of Myf5 and myo-
g e n i no nt h eTnni2 and Des promoters was confirmed
(data not shown). We next assayed for co-occupancy of
MyoD and myogenin. Cells were differentiated for three
days, immunoprecipitated with antibodies against MyoD
and subsequently immunoprecipitated with antibodies
against myogenin. Again, we observed co-occupancy of
M y o Da n dm y o g e n i no nt h eDes and Tnni2 promoters
(Figure 9B). Finally, we asked whether Myf5 and MyoD
co-occupy promoters. Differentiated cell extract was
immunoprecipitated with antibodies against Myf5 and
subsequently immunoprecipitated with antibodies
against MyoD. We observed that Myf5 and MyoD
co-occupied the Des and Tnni2 promoters (Figure 9B).
These data confirm that MyoD, myogenin and Myf5 are
bound to the same promoter elements.
Discussion
We have found that each muscle gene assayed showed a
unique temporal association of the MRFs and E pro-
teins. We were surprised to observe the dynamic and
transient roles of the MRFs on each of these promoters.
MyoD has been proposed to be a “pioneer” transcription
factor required to initiate the cascade of regulatory
events required to initiate expression of muscle-specific
genes [29]. MyoD recruits chromatin-modifying activ-
ities that alter both the regional histone modifications
and the chromatin remodeling at promoter binding sites
[7,30]. It is thought that these events then allow the
subsequent binding and transcriptional activity of myo-
genin. Our data are consistent with this model, as we
observed early associations of MyoD followed by the
association of myogenin. Our gene expression data also
show that for most genes examined in this study, the
recruitment of myogenin is coincident with high levels
of transcription. Our data are consistent with those
reported in other studies that showed that at the genes
whose expression marks late myogenesis, Ckm and Des,
MyoD is bound first, followed by the appearance of
myogenin, Mef2 (myocyte enhancer factor 2) and Brg1
(Brahma-related gene 1), the catalytic subunit of the
Swi/Snf chromatin remodeling complex [25]. In this
prior study, it was also shown that the recruitment of
myogenin was coincident with high levels of transcrip-
tion of these genes in embryonic tissue. In our study,
the peak of transcription and myogenin binding corre-
lated with high levels of RNAP II promoter occupancy
and histone H3 acetylation at the majority of genes
assayed. We note that the histone H3 acetylation levels
continued to rise following the departure of MyoD at
several genes. These data suggest that while MyoD may
be the initiating factor for chromatin modifications at
the promoter, the continued presence of MyoD is not
required for further increases in histone H3 acetylation.
The pattern of Myf5 binding was highly surprising. On
certain genes, the Myf5 binding pattern overlapped with
MyoD, but at other genes, the binding pattern over-
lapped with myogenin. In each case, the binding profile
of Myf5 suggests that Myf5 has a previously uncharac-
terized role in mediating gene expression in differentiat-
ing cells. While it is known that Myf5 cannot mediate
differentiation without myogenin or MyoD [8], our data
suggest that Myf5 does cooperate with both MyoD and
myogenin. Other groups have suggested that C2C12
cells, or the C2 cells used to derive them, have two
populations of myoblasts: a MyoD-expressing population
thought to be the differentiating population and a
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Figure 9 Myogenin and Myf5 colocalize in vivo and co-occupy promoters with MyoD. (A) Myf5 and myogenin colocalize on promoters
during embryonic development. Chromatin immunoprecipitation (ChIP) analysis was performed on skeletal muscle from E18.5 embryos. The
immunoprecipitated DNA was purified and amplified with primers specific to the promoter of leiomodin 2 (Lmod2) and desmin (Des). The fold
enrichment values were calculated as described in Methods. (B) Myf5, myogenin and MyoD co-occupy promoters. Cross-linked extracts from
myofibers in differentiation media for two days were immunoprecipitated with antibodies against the indicated antibody (1st IP) or IgG. The
immunoprecipitated complexes were released and immunoprecipitated again with antibodies against the indicated antibody (2nd IP). The
immunoprecipitated DNA was purified and amplified with primers specific to the promoters of Tnni2 and Des. Relative enrichment at the IgH
locus was used to normalize the data. The fold enrichment values were calculated as described in Methods.
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Myf5 [31,32]. However, in our studies, we can conclude
that Myf5 is expressed in differentiating cells and that it
colocalizes with MyoD and myogenin on specific pro-
moters in C2C12 cells. Our data are highly suggestive
that Myf5 plays a role in differentiation, but additional
experiments are required to confirm this hypothesis.
The binding pattern of myogenin was surprising as
well. The association of myogenin with muscle-specific
genes as cells began to differentiate was expected, as
myogenin is greatly upregulated at this time. However,
the relatively brief association of myogenin with target
genes was unexpected. A transient role of myogenin on
target genes has previously been suggested, as myogenin
appears to have distinct target gene sets during embryo-
genesis and in adult satellite cells and adult tissue
[26,33]. Our data suggest that myogenin may mediate
changes at the promoter that maintain high levels of
expression without the continued presence of myogenin.
Candidates for such a change include the switching of
core promoter complexes, which has been observed in
skeletal muscle differentiation. A TATA-binding protein
(TBP)-related factor, TRF3, and an associated TBP-asso-
ciated factor, TAF3, have been shown to be targeted by
MyoD to the myogenin promoter following differentia-
tion [31,34]. TBP is expressed in proliferating myoblasts,
but following differentiation, TBP is downregulated and
TRF3 and TAF3 are upregulated. It is also possible that
myogenin may direct epigenetic changes that maintain
gene expression.
The binding pattern of HEB was very surprising to us
as well. Detailed biophysical experiments have shown
that MRF and E protein heterodimers are highly stable
when bound to DNA. These studies have also indicated
that heterodimers likely form on the DNA. MyoD and
E47 heterodimers are not detected in diluted conditions
without DNA. However, in the presence of DNA, het-
erodimeric complexes are formed almost exclusively
[35]. Additional work has shown that the weak MyoD
homodimers and heterodimers that can form in the
absence of DNA are equally stable [36]. This suggests
that the MRFs and E proteins are likely to be mono-
meric in the cell. In this work {Maleki, 2002 #376}, it
was also shown that while MyoD or myogenin E protein
heterodimers on DNA were the most energetically
favorable, MyoD and myogenin homodimers can bind
E boxes with considerable positive cooperativity, while
E12 homodimers exhibited negative cooperativity. The
negative cooperativity of E12 suggests that the heterodi-
mer may form on DNA by binding of the E12 monomer
followed by binding of the MRF monomer.
Given these data, we anticipated detecting E proteins
o nt h eD N At h r o u g h o u tt h et i m ec o u r s eo fd i f f e r e n t i a -
tion. Instead, we found a highly dynamic pattern of
recruitment and release ofH E B .T h i sp a t t e r nw a sn o t
compensated by E12/E47, as we observed E12/E47 bind-
ing to only two of the promoters in this study at early
time points. At three days of differentiation, E12/E47
was not detected at any of the promoters analyzed. At
Des, the only gene highly expressed during proliferation
examined in this study, we did observe an association
with both E12/E47 and HEB in proliferating cells. At
Lmod2, we also observed an early recruitment of E12/
E47 and HEB, whereas we observed only late recruit-
ment of HEB at genes such as Tnni2.W eh y p o t h e s i z e
that E12/E47 might be required at a subset of genes
whose expression is immediately required as cells begin
to differentiate. While Lmod2 is not significantly
expressed in proliferating cells, Lmod2 is upregulated
very rapidly upon differentiation, and while the expres-
sion does continue to increase over an extended time
course, the expression increases only two fold. This is in
contrast to genes such as Tnni2, where the expression
level increases ten fold over the extended time course.
Lmod2 does not reach the high levels of transcription
seen at Tnni2 that coincide with the peak of HEB bind-
ing. It is possible that the early recruitment of E12/E47
and HEB at Lmod2 helps to support a relatively constant
level of expression that initiates immediately upon dif-
f e r e n t i a t i o n .I ti ss t r i k i n gt h a ta tb o t hg e n e sw h e r ew e
observed the binding of E12/E47, we also observed that
HEB appeared to replace E12/E47 as cells began to dif-
ferentiate. The binding pattern of HEB at Tcap is parti-
cularly interesting. HEB binding peaks at a time point
when no MRFs are detected. Reduced levels of binding
are detected at two additional time points when MyoD
and Myf5 are bound on the individual days. Thus, while
the HEB binding profile does overlap with MRF binding
as predicted by the biophysical studies, the occupancy of
HEB does not always overlap with the occupancy of the
MRFs.
While these data have revealed many novel findings
regarding the recruitment of the MRFs and E proteins,
many questions remain. The additional factors and
DNA elements that mediate the individual recruitment
and release of each of these factors remain to be charac-
terized. Many elegant studies of the role of chromatin
modification in muscle differentiation have suggested
that epigenetic events are important mediators in the
activation of muscle genes. The Swi/Snf chromatin
remodeling complex promotes muscle differentiation,
and it is known that the Swi/Snf complex is recruited to
both the Des and Ckm promoters studied here [25,37].
Important questions for future studies include how chro-
matin remodelers and chromatin-modifying enzymes
contribute to the recruitment and release of the myogenic
regulatory factors and E proteins to regulate muscle gene
expression.
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Here we have shown that MyoD, myogenin and Myf5
have sequential and transient roles on each of the pro-
moters assayed. For almost every gene assayed, we
found that the binding of myogenin and HEB correlated
with high levels of RNAP II occupancy, histone H3 acet-
ylation and the peak of transcription as assayed by
mRNA levels. We found that the primary E protein
recruited to late differentiation genes is HEB. At the few
promoters where E12/E47 was detected at early stages,
HEB replaced E12/E47 during differentiation. Finally, we
have shown that MyoD, myogenin and Myf5 colocalize
on promoters, suggesting that Myf5 contributes to the
gene expression of late differentiation genes.
Methods
Cell culture
Cells were grown in a humidified chamber at 37°C with
5% CO2. Proliferating C2C12 myoblasts (American Type
Culture Collection, Manassas, VA, USA) were grown in
Dulbecco’s modified Eagle’s medium (DMEM) supple-
mented with 10% fetal bovine serum (Thermo Scientific
HyClone, Logan, UT USA. To induce differentiation
into myotubes, cells were grown to 70% confluence and
media were switched to DMEM supplemented with 2%
horse serum (Thermo Scientific HyClone, Logan, UT
USA). C2C12 cells were grown in differentiation medium
for the number of days indicated in each experiment.
Western blot analysis
Cell extracts were made by lysing phosphate-buffered sal-
ine-washed cell pellets in radioimmunoprecipitation
assay buffer supplemented with protease inhibitors
(Complete Protease Inhibitor Cocktail Tablets; Roche
Applied Science, Indianapolis, IN USA. Following incu-
bation on ice, clear lysates were obtained by performing
centrifugation. Protein concentrations were determined
by using the Bio-Rad Protein Assay (Bio-Rad, Hercules,
CA USA. For each sample, 30 μg of protein were loaded
onto each gel. Proteins were transferred onto a nitrocel-
lulose membrane using a tank blotter (Bio-Rad, Hercules,
CA USA), then blocked using 5% milk and 1× Tris-buf-
fered saline plus Tween 20 (TBST) and incubated with
primary antibody overnight at 4°C. Membranes were
then washed with 1× TBST and incubated with the cor-
responding secondary antibody. Membranes were again
washed with 1× TBST, incubated with chemilumines-
cence substrate according to the manufacturer’s protocol
(SuperSignal West Pico Chemiluminescent Substrate;
Pierce Biotechnology, Rockford, IL USA and visualized
by autoradiography. The antibodies used include anti-
HEB (A-20; Santa Cruz Biotechnology, Santa Cruz, CA,
USA), anti-E12/E47 (Yae; Santa Cruz Biotechnology),
anti-Myf5 (C-20; Santa Cruz Biotechnology), anti-MyoD
(5.8A; Santa Cruz Biotechnology), anti-GAPDH (anti-gly-
ceraldehyde 3-phosphate dehydrogenase; Chemicon
International, Billerica, MA USA) and anti-MyoG (F5D)..
The F5D antibody developed by W. E. Wright was
obtained from the Developmental Studies Hybridoma
Bank under the auspices of the NICHD and maintained
by the University of Iowa, Department of Biology, Iowa
City, IA USA. Normal rabbit immunoglobulin G (IgG)
(Santa Cruz Biotechnology, Santa Cruz, CA USA) was
used as a nonspecific control.
Quantitative reverse transcriptase-polymerase chain
reaction assays
RNA was isolated from C2C12 cells by TRIzol reagent
extraction (Invitrogen, Carlsbad, CA. Two micrograms
of total RNA were reverse-transcribed with Multi-
Scribe™ Reverse Transcriptase (Applied Biosystems,
Carlsbad, CA USA. cDNA equivalent to 40 ng was used
for quantitative reverse transcriptase-polymerase chain
reaction (qRT-PCR) amplification (Applied Biosystems,
F o s t e rC i t y ,C AU S A )w i t hS Y B RG r e e nP C RM a s t e r
Mix (Applied Biosystems, Foster City, CA USA). Sam-
ples in which no RT was added were included for each
RNA sample. For measurements of relative gene expres-
sion, a fold change was calculated for each sample pair
and normalized to the fold change observed at HPRT.
mRNA expression levels were quantitated using a cali-
bration curve based on known dilutions of concentrated
cDNA. Each mRNA value was normalized to that of
HPRT. Fold change was calculated by dividing the
mRNA expression values of each sample pair. qRT-PCR
data were calculated using the comparative Ct method
(Applied Biosystems, Foster City, CA USA). Standard
deviations from the mean of the ΔCt values were calcu-
lated from three independent RNA samples and used to
generate error bars. Intron-spanning primers to the cod-
ing region of Lmod2, Des, Tnni2, Ckm and Tcap are
described in Additional file 1 Table S1. All qPCR assays
were performed in triplicate, and at least two indepen-
dent RNA samples were assayed for each time point.
ChIP assays
Cell culture ChIP assays were performed and quantified
as described previously [38] with the following modifica-
tions: 1 × 10
7 cells were used for each immunoprecipita-
tion, and protein A agarose beads (Invitrogen) were
used to immunoprecipitate the antibody-antigen com-
plexes. ChIP assays of embryonic tissue were performed
as previously described [26]. Limb tissue from wild-type
C57BL/6 mice{Jackson Laboratory, Bar Harbor, ME
USA) was isolated, cross-linked and enriched for nuclei.
Nuclear extracts of limb tissue were precleared using
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Page 16 of 18incubation with protein A agarose beads (Invitrogen,
Carlsbad, CA USA), which were also used to immuno-
precipitate the antibody complexes from tissue extracts
following antibody addition to the incubation mix. Anti-
bodies against the following proteins were used: MyoD
(5.8A; Santa Cruz Biotechnology, Santa Cruz, CA USA),
HEB (A-20; Santa Cruz Biotechnology, Santa Cruz, CA
USA), Myf5 (C-20; Santa Cruz Biotechnology, Santa
Cruz, CA USA), E proteins (Yae; Santa Cruz Biotechnol-
ogy, Santa Cruz, CA), myogenin (F5D; Developmental
Studies Hybridoma Bank), RNAP II (H-224; Santa Cruz
Biotechnology, Santa Cruz, CA USA) and histone H3
acetylated at lysine 9 and/or 18 (H3.Ac9/18; Millipore,
Billerica, MA USAUpstate Biotechnology. Primers span-
ning the described promoter elements of Lmod2, Des,
Tnni2, Ckm, Tcap, Myog, Tnnt2, Myh3 and Tnnc2 are
described in Additional file 1 Table S1. 2
-[Δ][Δ]Ct values
were calculated using the following formula based on
the comparative Ct method: ΔCt, template (antibody) -
ΔCt, template (IgG) = 2
-[Δ][Δ]Ct. Fold enrichments were
determined using the formula: 2
-[Δ][Δ]Ct (experimental)/
2
-[Δ][Δ]Ct (reference, IgH). The standard error of the
mean was calculated on the basis of replicate ΔCt values.
The immunoglobulin H (IgH) locus was used to normal-
ize the fold enrichments for the individual promoters.
All ChIP assays shown in the figures are representative
of at least three individual experiments.
ChIP-seq assay
ChIP-seq analysis was performed as previously described
[39] with antibodies against myogenin (F5D; Develop-
mental Studies Hybridoma Bank, Iowa City, IA USA)
and Myf5 (C-20; Santa Cruz Biotechnology, Santa Cruz,
CA USA).
shRNA knockdown
Cell lines depleted for HEB were constructed with
shRNA constructs designed by the RNAi Consortium in
the pLOK.1 plasmid (Open Biosystems, Huntsville, AL
USA). Five constructs targeting murine HEB and one
scrambled control were linearized, transfected into
C2C12 cells and selected with 2 μg/ml puromyosin.
Pooled clones were selected and propagated. Depletion
was confirmed at the RNA and protein levels. For the
HEB depletions, the expression of E12/E47 was also
confirmed at the RNA and protein levels.
Additional material
Additional file 1: Davie Supplemental figures and Table SM.
Supplemental Figures S1 through S6, Table 1 and supplemental methods
are included in this file.
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